AstraZeneca is best given to men only. This is the suggestion of the immunologist Antonella Viola and Massimo Andreoni, the head of Infectious Diseases of Tor Vergata. The first said her on Twitter about the proposal to authorize the Oxford Covid vaccine also to people under 60 years old. Andreoni, responding to the TV on Raitre said that it would be appropriate to also consider the correlation of rare thrombosis to the female gender that emerged from the vaccine studies.
AstraZeneca and Johnson & Johnson, Aifa prepares the green light for vaccines even for the fifties
AstraZeneca also to the under 60, in June 1 million vaccinated a day
«AstraZeneca even under 60? Not for all. The risk of serious side effects “of this Covid vaccine” is rare, but it is higher in young women. On the other hand, young women have a lower risk than men of developing severe symptoms from Covid-19. The risk-benefit ratio therefore suggests that we vaccinate all men, even with J&J, but to keep the age limit in place for women. Enough with the medicine that does not consider our sex ». So on social media Antonella Viola, immunologist at the University of Padua, after yesterday the coronavirus emergency commissioner, Francesco Paolo Figliuolo, explained that – as the prophylaxis campaign advances – the use of the AstraZeneca vaccine will also be re-evaluated for the under 60 group.
Covid, different immune response for women and men? The study that explains who activates the most sentinel cells
Andreoni too – “If we entered the order of ideas to vaccinate” against Covid-19 “with AstraZeneca even under 60 years, and I would not be against it, maybe some limitations could be created which are also understandable “. This is the thought expressed by Massimo Andreoni, scientific director of the Italian Society of Infectious and Tropical Diseases (Simit) and head of Infectious Diseases at the Tor Vergata Polyclinic in Rome, guest at ‘Agorà’ on Rai3. What kind of limitations? «Please note that these exceptional events», the rare thrombosis which have been evaluated by the European Medicines Agency Ema, “substantially concerned the female gender and therefore we could try to give a technical explanation to the choices that are made, trying to make people understand them ».